USANA Health Sciences (NYSE:USNA) Sets New 1-Year Low – Here’s What Happened

USANA Health Sciences, Inc. (NYSE:USNA)’s stock price hit a new 52-week low during trading on Tuesday . The company traded as low as $26.74 and last traded at $26.87, with a volume of 26579 shares traded. The stock had previously closed at $27.24.

Analyst Upgrades and Downgrades

Several research firms have weighed in on USNA. Sidoti downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 18th. StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, February 14th. Finally, DA Davidson decreased their price target on USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a research note on Thursday, February 27th.

USANA Health Sciences Trading Down 2.2 %

The business’s fifty day simple moving average is $31.67 and its 200-day simple moving average is $35.33. The firm has a market cap of $503.67 million, a P/E ratio of 9.38, a price-to-earnings-growth ratio of 0.93 and a beta of 0.98.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.15. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The company had revenue of $213.61 million for the quarter, compared to the consensus estimate of $208.82 million. Analysts anticipate that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

Insider Activity at USANA Health Sciences

In related news, insider Joshua Foukas sold 5,732 shares of the business’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $32.54, for a total transaction of $186,519.28. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David Mulham Mulham sold 3,234 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $32.98, for a total transaction of $106,657.32. Following the transaction, the insider now directly owns 12,775 shares of the company’s stock, valued at $421,319.50. This represents a 20.20 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 15,920 shares of company stock worth $500,285 over the last ninety days. 0.33% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On USANA Health Sciences

Institutional investors have recently modified their holdings of the stock. Pzena Investment Management LLC boosted its stake in USANA Health Sciences by 3.6% in the 4th quarter. Pzena Investment Management LLC now owns 1,087,076 shares of the company’s stock worth $39,015,000 after purchasing an additional 37,466 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of USANA Health Sciences by 7.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 773,228 shares of the company’s stock worth $27,751,000 after buying an additional 55,059 shares in the last quarter. Pacer Advisors Inc. grew its holdings in shares of USANA Health Sciences by 8.8% during the fourth quarter. Pacer Advisors Inc. now owns 592,001 shares of the company’s stock valued at $21,247,000 after buying an additional 47,745 shares during the last quarter. State Street Corp increased its position in shares of USANA Health Sciences by 0.6% during the third quarter. State Street Corp now owns 435,164 shares of the company’s stock valued at $16,501,000 after acquiring an additional 2,782 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in USANA Health Sciences by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 301,949 shares of the company’s stock worth $10,839,000 after acquiring an additional 4,829 shares during the last quarter. 54.25% of the stock is owned by hedge funds and other institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.